Compare INCR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | XLO |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 49.8M |
| IPO Year | 2021 | 2021 |
| Metric | INCR | XLO |
|---|---|---|
| Price | $0.88 | $7.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 30.5K | 28.5K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $69.54 | N/A |
| Revenue Next Year | $41.75 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.68 | $0.46 |
| 52 Week High | $1.77 | $9.25 |
| Indicator | INCR | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 52.36 |
| Support Level | $0.84 | $7.47 |
| Resistance Level | $0.93 | $8.80 |
| Average True Range (ATR) | 0.07 | 0.37 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 6.24 | 51.64 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.